- Patients
- Clinical Research
- Find a clinical trial
- HLX22-GC-301
Gastric
HLX22-GC-301
A Randomized, Double-blinded, Multicentre, Phase Ⅲ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Trial overview
Medical Oncology
Gastric
Gastroinstestinal
III
Registration number: NCT06532006
Campbelltown (Oncology)
38 Camden Road, Campbelltown, NSW, 2560, Australia

Clinical trials enquiries
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.